GlassScriptPhysician profile
Richa Shukla
NPI 1992029979
$99,913.40
in general payments reported to CMS, 2019-2025
24 companies · $30K in 2025
The $30K reported for 2025 was more than what 96% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2020: $156 · 2021: $7,026 · 2022: $11K · 2023: $20K · 2024: $31K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $68K · Food and Beverage: $5,947 · Travel and Lodging: $5,160 · Consulting Fee: $1,605 · Education: $192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $68,012.50 |
| Food and Beverage | $5,946.68 |
| Travel and Lodging | $5,159.73 |
| Consulting Fee | $1,605.00 |
| Education | $191.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $78,607.06 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Lilly USA, LLC | $12,968.16 | 2023-2025 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $4,135.31 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Scientific Affairs, LLC | $2,071.37 | 2019-2024 | Tremfya, Remicade, Stelara |
| Janssen Biotech, INC. | $907.83 | 2019-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $348.45 | 2019-2025 | Xifaxan |
| Erbe USA INC | $166.96 | 2023-2025 | Vio3apc3, Erbe Vio3 Apc3 |
| Intercept Pharmaceuticals, INC. | $135.12 | 2022-2025 | Ocaliva |
| Pfizer INC. | $131.86 | 2019-2025 | |
| Organon LLC | $83.17 | 2021-2023 | Renflexis |
| Ipsen Biopharmaceuticals, INC | $80.21 | 2023-2025 | Bylvay, Iqirvo |
| Merck Sharp & Dohme LLC | $63.86 | 2019-2024 | Dificid |
| Redhill Biopharma INC. | $44.46 | 2021-2022 | |
| Orphalan INC | $42.71 | 2023-2024 | Cuvrior |
| Phathom Pharmaceuticals, INC. | $40.31 | 2024 | Voquezna |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $40.08 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $21.51 | 2023 | |
| Celgene Corporation | $13.37 | 2021 | |
| Shire North American Group INC | $11.60 | 2019 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richa Shukla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.